



Press Release

Copenhagen, December 26, 2007

Seventure Partners, one of the most active foreign investors in Scandinavia and the only French shareholder in Danish company Santaris Pharma, is pleased to announce the signature of a major R&D agreement with GlaxoSmithKline

Santaris Pharma, a Danish biopharmaceutical company specializing in the development of RNA antagonists, has announced the signature of a global R&D agreement with GSK to discover, develop and market anti-viral RNA antagonist drugs.

Under the terms of the agreement, GSK will make an equity investment of \$5 million in Santaris Pharma and pay upfront fees and milestone payments that could represent a total of \$700 million depending on the development of the products.

The company currently has cash reserves of over €40 million and more than 85 employees.

Santaris Pharma also has a global partnership agreement with US company Enzon Pharmaceuticals for the joint development and marketing of a series of RNA antagonists in oncology.



About Seventure Partners:

An active partner of companies presenting strong growth potential, Seventure Partners has been investing in innovative sectors since 1997, focusing in particular on French and European companies operating in the ITC and life sciences industries. With some €400 million in assets under management, Seventure Partners stands out as one of Europe's leading VC players. Seventure Partners is a subsidiary of Natixis Private Equity, one of Europe's foremost private equity investors.

In life sciences, our four main investment sectors are biotechnology and pharmaceutical R&D, medical equipment, industrial chemistry and biotechnology and nutrition. However, we also invest in diagnostics, galenic improvements, environmental services, bio-energy, skin care, well-being and services.

For more information about Seventure Partners: www.seventure.fr

For more information about Santaris Pharma:

Dr Keith McCullagh, President & CEO, Santaris Pharma A/S, Copenhagen, Denmark. Phone: +45 4517 9819 km@santaris.com	Henrik Stage, Vice-President & CFO, Santaris Pharma A/S, Copenhagen, Denmark. Phone: +45 4517 9888 hs@santaris.com
--	---

Press contacts:

Seventure Isabelle de Crémoux Member of the Board and Director of the Life Sciences Department Phone: +33 (0)1 58 19 22 77 isabelle.decremoux@seventure.fr	HDL Communication Delphine Rouget Phone: +33 (0)1 58 65 00 78 drouget@hdlcom.com
---	--